CD8A and neoplasm: It is conceivable that the dual role of Bevacizumab on ECs and T cells can facilitate the infiltration of CD8+ T cells into tumours and enable direct tumour cell killing as they are the main lymphocytes in cell-mediated antitumor immunity [48,49].